SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is experiencing a volatile trading session following its WWDC keynote, as investors react to new Siri AI features and an artificial intelligence partnership with Google. While some traders are focused on a typical 'sell the news' price decline, the community is actively debating the company's competitive standing in the AI landscape compared to its peers.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is experiencing significant downward pressure as investors rotate capital ahead of an anticipated major IPO, leading to heavy volatility and active discussions about whether this decline is a temporary consolidation or a sign of a deeper correction. Despite the price action, long-term investors remain focused on the company's aggressive infrastructure expansion and strategic position in the AI compute market, viewing current pullbacks as potential buying opportunities.

AmpliTech Group, Inc. engages in the design, development, and manufacture of radio frequency components. It offers signal processing components for satellite and 5G communications networks, defense, space, and other commercial applications. Its products include amplifiers, passive components, mechanical drawings, monolithic microwave integrated circuit, and 5G. The company was founded by Fawad Maqbool in 2002 and is headquartered in Hauppauge, NY.

Amplitech Group Inc

Amplitech Group is experiencing significant market attention driven by its recent FCC and Canadian ISED certifications, which clear the way for immediate commercial deployment of its 5G Native DAS solution. The community is actively discussing the stock's potential for a major rerating as the company transitions from a research-focused entity to an infrastructure player with a multi-million dollar backlog, while also monitoring potential catalysts from the expanding AI-RAN and satellite sectors.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending as retail investors engage in a heated debate over whether the stock's recent decline to multi-year lows represents a deep-value opportunity or a permanent loss of competitive relevance. While some participants are accumulating shares based on low forward price-to-earnings metrics and potential institutional backing, others are aggressively shorting the name, citing fundamental concerns regarding revenue contraction and stiff competition from modern fintech alternatives.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis

Trulieve Cannabis is trending as the community closely monitors the company's historic NYSE uplisting, with investors actively discussing potential institutional interest, the impact of federal reclassification on profitability, and speculation surrounding CEO Kim Rivers' involvement in high-level government cannabis discussions. Market participants remain focused on whether this regulatory shift and major exchange debut will provide the sustained momentum needed to overcome historical OTC volatility and short interest.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is attracting significant community attention as investors position for a highly anticipated 52-week data release from their VELA trials, with many speculating an imminent announcement could trigger a major revaluation or M&A activity. Market participants are intensely debating the timing of this data drop in relation to the company's scheduled investor conference appearances, while keeping a close eye on institutional block trading and potential short squeezes as the company progresses toward commercialization.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is currently trending due to the EMA's recommendation to approve its oral Wegovy pill in Europe, a milestone that positions the company to potentially lead the oral obesity treatment market in the region. Community discussion remains polarized, with many investors debating the impact of increasing competition from Eli Lilly's pipeline versus Novo Nordisk's established first-mover advantage and expanding global footprint.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as investors digest mixed sentiment surrounding the company's recent obesity drug clinical trial data and a newly announced oncology collaboration with Innovent Biologics. The community is actively debating the stock's long-term potential as a defensive dividend play versus concerns over leadership, valuation stagnation, and its ability to compete in the high-growth weight-loss drug market.

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

Tango Therapeutics Inc

Tango Therapeutics is trending as investors react to clinical updates on its PRMT5 inhibitor program, balancing excitement over a new brain-penetrant candidate and upcoming combination trials with concerns regarding the discontinuation of earlier assets. The community is actively debating the company's long-term potential, with bulls citing a deep institutional pipeline and potential buyout value, while skeptics focus on the recent price volatility and the dilution risks associated with financing clinical milestones.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending as investors react to a significant patent exclusivity extension through 2041, fueling speculation about long-term valuation and potential acquisition. The community is focused on the upcoming earnings report and the company's progress toward European regulatory approval as key catalysts for a potential rerating.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FS Specialty Lending Fund (FSSL) Declares Distribution for May 2026

FS Specialty Lending Fund (FSSL) Declares Distribution for May 2026 FS Specialty Lending Fund (FSSL) Declares Distribution for May 2026 PR Newswire PHILADELPHIA, May 7, 2026 PHILADELPHIA, May 7, 2026...

FS Specialty Lending Fund (FSSL) Declares Distribution for April 2026

FS Specialty Lending Fund (FSSL) Declares Distribution for April 2026 FS Specialty Lending Fund (FSSL) Declares Distribution for April 2026 PR Newswire PHILADELPHIA, April 6, 2026 PHILADELPHIA, April...

FS Specialty Lending Fund (FSSL) Declares Distribution for March 2026

FS Specialty Lending Fund (FSSL) Declares Distribution for March 2026 FS Specialty Lending Fund (FSSL) Declares Distribution for March 2026 PR Newswire PHILADELPHIA, March 10, 2026 PHILADELPHIA...

FS Specialty Lending Fund (FSSL) Declares Distribution for January 2026

FS Specialty Lending Fund (FSSL) Declares Distribution for January 2026 FS Specialty Lending Fund (FSSL) Declares Distribution for January 2026 PR Newswire PHILADELPHIA, Jan. 12, 2026 PHILADELPHIA...

FS Specialty Lending Fund (FSSL) Declares Distribution for Fourth Quarter of 2025

FS Specialty Lending Fund (FSSL) Declares Distribution for Fourth Quarter of 2025 FS Specialty Lending Fund (FSSL) Declares Distribution for Fourth Quarter of 2025 PR Newswire PHILADELPHIA, Nov. 14...

Current Price	$11.33
Prev Close	$11.35
Open	$11.32
Dividend Yield	N/A
50-Day Moving Average	$12.02
Beta	N/A
Avg. Volume	290,362.07
PE Ratio	N/A

52-Week High	$15.00
52-Week Low	$11.00
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

FSSLFS Specialty Lending Fund

Fundamentals

Feed

News

Sentiment

Fundamentals

Info

Latest FSSL News